BMS-986094

BMS-986094 (formerly known as INX-189 and INX-08189) is a small molecule nucleotide analog prodrug developed as an inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase NS5B. It was designed to be rapidly metabolized in hepatocytes to its active form, 2'-C-methyl guanosine triphosphate, which inhibits HCV replication by targeting the viral polymerase. The drug demonstrated potent antiviral activity in preclinical and early clinical studies but was discontinued during Phase II development due to serious safety concerns, including heart and kidney toxicity that led to patient hospitalizations and at least one death. Mechanistic studies suggest that mitochondrial toxicity—possibly through inhibition of mitochondrial RNA polymerase—may have contributed to these adverse effects. Development was halted by Bristol Myers Squibb in 2012 following FDA clinical hold[1][3][4][6].

Other names

BMS 986094BMS986094BMS-986094INX 08189INX08189INX-08189